Primary results
| Result | Overall (N = 111) | IV tPA (N = 30) | No IV tPA (N = 81) | P Value* |
|---|---|---|---|---|
| Revascularization postretriever, N (%) | 60 (54.1) | 16 (53.3) | 44 (54.3) | >.99 |
| Revascularization postadjuvant, N (%) | 77 (69.4) | 22 (73.3) | 55 (67.9) | .649 |
| mRS ≤2 at 90 d, N (%)† | 37 (34.3) | 10 (33.3) | 27 (34.6) | >.99 |
| Mortality at 90 d, N (%)† | 33 (30.6) | 8 (26.7) | 25 (32.1) | .647 |
| Intracranial hemorrhage | ||||
| Symptomatic ICH,‡ N (%) | 10 (9.0) | 2 (6.7) | 8 (9.9) | .726 |
| Asymptomatic ICH,§ N (%) | 33 (29.7) | 12 (40) | 21 (25.9) | .166 |
| Procedure-related serious adverse events, N (%) | 11 (9.9) | 0 (0) | 11 (13.6) | .034 |
| Dissection | 3 (2.7) | 0 | 3 (3.7) | .562 |
| Perforation¶ | 3 (2.7) | 0 | 3 (3.7) | .562 |
| Embolization of a previously uninvolved vessel | 1 (0.9) | 0 | 1 (1.2) | >.99 |
| Groin complications | 0 | 0 | 0 | |
| Symptomatic ICH not associated with perforation‖ | 3 (2.7) | 0 | 3 (3.7) | .562 |
| Asymptomatic SAH associated with death | 1 (0.9) | 0 | 1 (1.2) | >.99 |
| Clinically significant procedure complications, N (%) | 5 (4.5) | 0 (0) | 5 (6.2) | .321 |
Note:—IV tPA indicates intravenous tissue plasminogen activator; mRS, modified Rankin score; ICH, intracranial hemorrhage; SAH, subarachnoid hemorrhage.
* Fisher exact test.
† N = 108 (data not available at 90 days in 3 patients in the no IV tPA group).
‡ Includes 3 patients with symptomatic SAH, all within the no IV tPA group. Symptomatic hemorrhage includes 6 hemorrhages adjudicated as evolution of the primary stroke and 4 that were adjudicated as procedure-related as detailed below.
§ Includes 8 patients with asymptomatic SAH; 4 were in the IV tPA group and 4 were in the IV tPA group.
¶ One perforation lead to symptomatic hemorrhage.
‖ Patients in whom the symptomatic ICH was either caused by the procedure or the procedure could not be ruled out as the cause of the hemorrhage.